iCell® DopaNeurons Kit, 01279

Dopaminergic neurons derived from human iPS cells, frozen

More Views

0 USD

Options

* Required Fields

Catalog # (Select a product)
Dopaminergic neurons derived from human iPS cells, frozen

Overview

CDI’s induced pluripotent stem (iPS) cell platform uniquely enables the large-scale manufacture of iCell® DopaNeurons, human floor plate-derived midbrain dopamine (DA) neurons. DA neurons derived from the floor plate are the only DA neurons that have been shown to engraft in animals, making them a leading candidate for use in clinical applications.


iCell® DopaNeurons exhibit the relevant biology and functionality to advance research and preclinical studies for devastating neurological disorders:
• Fully differentiated, > 80% pure midbrain DA neurons
• Expression of relevant midbrain DA neuron markers (e.g. Lmx1, FoxA2, and TH)
• Functional release and uptake of dopamine
• Appropriate electrophysiology and pacemaker-like activity: (1) Spontaneous and evoked action potentials, (2) excitatory post-synaptic currents and (3) sodium ion and potassium ion channel currents
• Compatible with a wide range of biochemical and cell-based assays, including: (1) Cell viability, (2) cell mitophagy, (3) calcium signaling and (4) neurite outgrowth and retraction


Certain products are only available in select territories. Please contact your local Sales Representative or Product & Scientific Support at techsupport@stemcell.com for further information. Please note that this product requires that the end-user signs a Letter of Acknowledgement before purchasing.
Components:
iCell® DopaNeurons Kit, 01279, 1 x 10^6 cells (Catalog #R1088)
          iCell® DopaNeurons, 01279, 1 x 10^6 cells
          iCell® Neural Base Medium 1, 100 mL
          iCell® Neural Supplement B, 2 mL
          iCell® Nervous System Supplement, 1 mL
 
iCell® DopaNeurons Kit, 01279, 5 x 10^6 cells (Catalog #R1032)
          iCell® DopaNeurons, 01279, 5 x 10^6 cells
          iCell® Neural Base Medium 1, 100 mL
          iCell® Neural Supplement B, 2 mL
          iCell® Nervous System Supplement, 1 mL  
 
iCell® DopaNeurons Kit 3 pack, 01279, 3 vials x 1 x 10^6 cells (Catalog #R1108)
          iCell® DopaNeurons, 01279, 3 vials x 1 x 10^6 cells
          iCell® Neural Base Medium 1, 100 mL
          iCell® Neural Supplement B, 2 mL
          iCell® Nervous System Supplement, 1 mL
Subtype:
Frozen
Cell Type:
Neural Cells, PSC-Derived
Species:
Human
Cell and Tissue Source:
Pluripotent Stem Cells
Brand:
iCell
Donor Status:
Normal

Scientific Resources

Educational Materials

(11)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications

(2)
Stem cell reports 2017

Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In Vivo.

D. R. Wakeman et al.

Abstract

A major challenge for clinical application of pluripotent stem cell therapy for Parkinson's disease (PD) is large-scale manufacturing and cryopreservation of neurons that can be efficiently prepared with minimal manipulation. To address this obstacle, midbrain dopamine neurons were derived from human induced pluripotent stem cells (iPSC-mDA) and cryopreserved in large production lots for biochemical and transplantation studies. Cryopreserved, post-mitotic iPSC-mDA neurons retained high viability with gene, protein, and electrophysiological signatures consistent with midbrain floor-plate lineage. To test therapeutic efficacy, cryopreserved iPSC-mDA neurons were transplanted without subculturing into the 6-OHDA-lesioned rat and MPTP-lesioned non-human-primate models of PD. Grafted neurons retained midbrain lineage with extensive fiber innervation in both rodents and monkeys. Behavioral assessment in 6-OHDA-lesioned rats demonstrated significant reversal in functional deficits up to 6 months post transplantation with reinnervation of the host striatum and no aberrant growth, supporting the translational development of pluripotent cell-based therapies in PD.
Cell 2016 OCT

Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells.

G. La Manno et al.

Abstract

Understanding human embryonic ventral midbrain is of major interest for Parkinson's disease. However, the cell types, their gene expression dynamics, and their relationship to commonly used rodent models remain to be defined. We performed single-cell RNA sequencing to examine ventral midbrain development in human and mouse. We found 25 molecularly defined human cell types, including five subtypes of radial glia-like cells and four progenitors. In the mouse, two mature fetal dopaminergic neuron subtypes diversified into five adult classes during postnatal development. Cell types and gene expression were generally conserved across species, but with clear differences in cell proliferation, developmental timing, and dopaminergic neuron development. Additionally, we developed a method to quantitatively assess the fidelity of dopaminergic neurons derived from human pluripotent stem cells, at a single-cell level. Thus, our study provides insight into the molecular programs controlling human midbrain development and provides a foundation for the development of cell replacement therapies.
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.